发明名称 Triazolyl PDE10 inhibitors
摘要 The present invention is directed to substituted triazolyl compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
申请公布号 US9200001(B2) 申请公布日期 2015.12.01
申请号 US201214349030 申请日期 2012.10.03
申请人 Merck Sharp & Dohme Corp. 发明人 Cox Christopher D.;Dudkin Vadim Y.;Kim June J.;Kuduk Scott D.;McVean Carol A.;Reger Thomas;Sheen Justin T.;Steele Thomas
分类号 C07D403/14;A61K31/4196;C07D487/04;C07D401/14;C07D417/14;C07D403/04;C07D405/14;C07D413/14;C07D471/04 主分类号 C07D403/14
代理机构 代理人 Ayler Sylvia A.;Todaro John C.
主权项 1. A compound of the formula I: wherein: W, X, Y, and Z are independently selected from the group consisting of: X=Y=N and Z=W=C, X=Z=N and Y=W=C, and Y=Z=N and X=W=C, R represents H, or C1-6alkyl, R1 is selected from the groups consisting of, (CH2)nOR, (CH2)nC3-10 cycloalkyl, (CH2)nC6-10 aryl, C1-6alkyl, and (CH2)nC5-10 heterocycle, said alkyl, cycyloalkyl, heterocycle, and aryl optionally substituted with 1 to 3 groups of Ra; R2 is selected from the group consisting of: (1) halogen, (2) C1-6alkyl, which is unsubstituted or substituted with 1 to 3 groups of Ra, (3), (4) —(CH2)nC5-10 heterocycle, which is unsubstituted or substituted with 1 to 3 groups of Ra, (5) —(CH2)nC3-10 cycloalkyl, which is unsubstituted or substituted with 1 to 3 groups of Ra, (6) C2-6alkenylC5-10 heterocycle, which is unsubstituted or substituted with 1 to 3 groups of Ra; (7) C2-6alkynylC5-10 heterocycle, which is unsubstituted or substituted with 1 to 3 groups of Ra; and (8) C2-6alkenyl, which is unsubstituted or substituted with 1 to 3 groups of Ra; R3 and R4 are absent when Z or W is N, and are independently selected from the group consisting of H, —O—R, CN, O(CH2)nOR, —OCHR(CH2)nOR, SR, SO2R, S(O)R, C(O)N(R)2, C1-3 haloalkyl, O(CH2)nC1-3haloalkyl, —O(CH2)nC3-6cycloalkyl, (CH2)nC5-10heterocycle, —O(CH2)nC5-10heterocycle, C1-6alkyl, and C3-10cycloalkyl when Z or W is C, said alkyl, cycloalkyl, and heterocycle unsubstituted or substituted with 1 to 3 groups of Ra; R5 and R6 are absent when X or Y is N, and are independently selected from the group consisting of H, and CN, when X or Y is C; R7 is selected from the group consisting of C1-6 alkyl, or halo; Ra is selected from the group consisting of: (1) halogen, (2) hydroxyl, (3) C1-6alkyl, (4) —(CH2)nO—R, (5) (CH2)n C6-10aryl, (6) (CH2)nC5-10 heterocycle, (7) OC1-5 haloalkyl; (8) CO2R; (9) C(O)N(R)2; (10) (CH2)nC(O)R; (11) CN, (12) (CH2)nN(R)2; (13) (CH2)nC3-6cycloalkyl, (14) (CH2)nC1-3 haloalkyl; said cycloalkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of Rb; Rb is selected from the group consisting of (CH2)nC1-3 haloalkyl; (CH2)nC3-6cycloalkyl, (CH2)nC5-10 heterocycle, (CH2)nC6-10 aryl, (CH2)nN(R)2, halogen, CN, OC1-4 haloalkyl, C1-6 alkyl, and OR, said heterocycle unsubstituted or substituted with 1 to 3 groups of C1-6 alkyl; and n represents 0-4, or a pharmaceutically acceptable salt thereof, wherein C5-10 heterocycle is a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S and R1 and R7 are not both hydrogen at the same time and R2 and R3 are not C1-6 alkyl at the same time.
地址 Rahway NJ US